Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova最新文献

{"title":"[Digital technologies in the diagnosis and treatment of sleep disorders in patients with post-traumatic stress disorder].","authors":"E A Cheremushkin, Yu V Ukraintseva","doi":"10.17116/jnevro202612605287","DOIUrl":"10.17116/jnevro202612605287","url":null,"abstract":"<p><p>Sleep disorders are a primary symptom of post-traumatic stress disorder (PTSD). Advances in computer technology have enabled the development of widely accessible wearable devices (WDs) that record objective parameters of patient activity and physiological functions. When integrated into telemedicine platforms, these devices facilitate patient access to diagnostic and treatment methods. This review summarizes the use of WDs, mobile, and web applications for diagnosing sleep disorders in PTSD and evaluating the effectiveness of therapeutic interventions. The application of modern technologies in research to establish new treatment approaches for PTSD and to translate scientific developments into clinical practice is discussed. The review also analyzes the use of computerized therapies that enable remote and largely autonomous treatment. Issues related to the use of digital technologies for diagnosing and treating PTSD are addressed, including confidentiality, security, and the need for careful interpretation of results, particularly for patients with mental disabilities and cognitive deficits.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 5. Vyp. 2","pages":"87-94"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148213526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Predictive epileptology: the emergence of a new paradigm for the management of epileptic seizures].","authors":"F A Yusupov, M Sh Abdykadyrov","doi":"10.17116/jnevro202612605114","DOIUrl":"10.17116/jnevro202612605114","url":null,"abstract":"<p><strong>Objective: </strong>To assess the current state and potential use of wearable devices with artificial intelligence (AI) for the prediction of epileptic seizures.</p><p><strong>Material and methods: </strong>Scientific papers published within the last five years were used for this review, except for fundamental publications. The literature was selected from scientific databases Scopus, PubMed, Google Scholar, and eLibrary.</p><p><strong>Results: </strong>The findings indicate that predicting epileptic seizures with AI-based wearable devices is technologically feasible. Contemporary algorithms, particularly personalized deep learning models, demonstrate predictive accuracy that surpasses random chance by analyzing data from multimodal sensors. Nevertheless, a substantial gap persists between the high accuracy observed in laboratory settings and the more moderate, though clinically meaningful, performance in real-world environments. For patients, these technologies offer significant benefits, including reduced chronic anxiety, enhanced safety, and improved autonomy. Major barriers to widespread adoption include elevated false alarm rates, challenges in predicting non-motor seizures, and considerable regulatory, ethical, and economic constraints.</p><p><strong>Conclusion: </strong>Wearable AI-based devices mark a fundamental shift in epilepsy management from reactive response to proactive risk management. While the technology has proven its great potential, it is not yet ready for mass clinical introduction due to existing technical and non-technical barriers. The future of this area lies in the development of integrated «closed-loop» systems that automatically trigger therapeutic interventions based on accurate prognoses. Ultimately, these innovations are not just technological advances, but powerful tools that can improve the quality of life for millions of people.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 5","pages":"14-20"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148165810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correction of autonomic nervous system disorders: results from an observational study].","authors":"L A Skipetrova, R A Cheremin, I G Savinkova","doi":"10.17116/jnevro202612605157","DOIUrl":"10.17116/jnevro202612605157","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of Prospekta in real-world clinical settings for the treatment of autonomic nervous system (ANS) disorders in patients presenting with asthenia.</p><p><strong>Material and methods: </strong>This observational study included 425 patients, comprising individuals of both sexes aged 18 to 55 years (mean age 38.4±10.8 years), who reported symptoms associated with ANS disorders and fatigue. Participants received Prospekta, administered as 1 tablet twice daily for 4 weeks. The severity of ANS disorders was evaluated using the 4DSQ (Four Dimensional Symptom Questionnaire) somatoform disorder scale. Quality of life was measured employing the EQ-5D-3L questionnaire. The mean Clinical Global Impression - Improvement (CGI-I) score, along with the nature and frequency of adverse events during treatment, their severity, relationship to Prospekta, and outcomes, were comprehensively recorded.</p><p><strong>Results: </strong>Patients were categorized into three groups based on their initial level of somatization. A statistically significant reduction in the mean 4DSQ score was noted across all groups, with the most significant improvement observed in Group 3 (characterized by a severely elevated level of somatization) (<i>p</i><0.001). Additionally, an improvement in quality of life, as assessed by the EQ-5D-3L questionnaire, was statistically significant. A positive correlation was identified between the decrease in somatization severity and reductions in both blood pressure and heart rate.</p><p><strong>Conclusion: </strong>The use of Prospekta in patients with ANS disorders and asthenia results in a significant decrease in somatization, which corresponds with normalization of cardiovascular function and improvements in quality of life.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 5","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148165711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Speech signal acoustic analysis in the diagnosis of neurological and mental diseases: a systematic review and meta-analysis].","authors":"A A Garanin, O Yu Aydumova, A O Rubanenko, A R Khumorova, A V Kolsanov","doi":"10.17116/jnevro202612603138","DOIUrl":"10.17116/jnevro202612603138","url":null,"abstract":"<p><strong>Objective: </strong>To assess speech signal acoustic parameters for the diagnosis of neurological and mental diseases.</p><p><strong>Material and methods: </strong>The data were searched in accordance with the PRISMA requirements and guidelines across the PubMed, Google Scholar, ClinicalTrials.gov, CyberLenink, and eLibrary databases. Seven publications were selected for the final analysis of full-text articles. These papers evaluated the parameters of the speech signal in patients with Parkinson's disease, Alzheimer's disease, and primary depression. The meta-analysis examined Jitter and Shimmer in patients' speech signals compared with those of healthy volunteers.</p><p><strong>Results: </strong>Six studies were included in the meta-analysis in assessing the diagnostic capabilities of changes in fundamental tone frequency (Jitter) for neurological and mental diseases. The meta-analysis included 180 patients and 193 healthy volunteers. According to the results, Jitter was significantly more pronounced in patients with Alzheimer's disease, depression, and Parkinson's disease than in healthy volunteers (mean difference 0.786 (0.481-1.091), I²=45.83%, <i>p</i><0.001). The meta-analysis of speech-signal acoustic analysis results for diagnosing neurological and mental diseases, based on changes in signal amplitude (Shimmer), included 7 studies involving 222 patients and 295 healthy volunteers. There was no statistically significant difference in Shimmer in patients with Alzheimer's disease, depression, and Parkinson's disease, compared to patients without diseases (mean difference 0.392 (-0.179-0.962), I²=88.86%, <i>p</i>=0.178).</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis of studies have shown the potential of acoustic analysis of the speech signal for diagnosing neurological and mental diseases. Jitter is a reliable diagnostic criterion for the presence and progression of neurological and mental diseases.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 3","pages":"38-44"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147693924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Gerstmann-Sträussler-Scheinker disease].","authors":"E A Katunina, I A Putyatin, M B Dolgushin, R V Nadelyaev","doi":"10.17116/jnevro2026126041143","DOIUrl":"10.17116/jnevro2026126041143","url":null,"abstract":"<p><p>Prion diseases are a group of rare neurodegenerative diseases with a challenging diagnosis due to their phenotypic heterogeneity. One of the genetic forms of prion proteopathies is Gerstmann<i>-</i>Sträussler<i>-</i>Scheinker disease (GSSD). The article presents a clinical case of a patient with progressive cerebellar ataxia and mild cognitive and behavioral disorders who has been verified as having GSSD. The specific feature of the case was the use of positron emission tomography with ¹⁸F-fluorodeoxyglucose to identify regional metabolic disorders in the basal ganglia and cerebellum before the appearance of MRI changes and apparent clinical manifestations. The challenges of differential diagnosis with other neurodegenerative diseases associated with cognitive and cerebellar disorders, as well as the relevance of considering prion diseases in this differential diagnosis, are discussed.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 4","pages":"143-149"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147944003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Acute vestibular syndrome: from diagnosis to rehabilitation].","authors":"A V Amelin, A L Guseva, M A Domashenko, M V Zamergrad, G E Ivanova, Ju V Kotovskaja, A A Kulesh, V A Parfenov, N K Runihina, N A Suponeva, O N Tkacheva","doi":"10.17116/jnevro202612603221","DOIUrl":"10.17116/jnevro202612603221","url":null,"abstract":"<p><p>The management of patients with acute vestibular vertigo remains a challenging and pressing issue in modern medicine due to the variety of etiological factors, the subjective nature of patient complaints, and the limited application of existing neurovestibular diagnostic algorithms in real-world clinical practice. Despite numerous publications on the management of patients with acute vestibular vertigo, certain issues regarding examination and treatment pathways remain unresolved. Approximately a quarter of conditions presenting with acute vestibular syndrome (AVS) are caused by stroke or other life-threatening diseases, so urgent diagnostics are always necessary. Due to the insufficient information from neuroimaging methods in patients with isolated vestibular vertigo, clinical diagnosis becomes paramount, requiring specialized training from physicians. Patients with peripheral causes of AVS and vestibular migraine often do not receive fully effective treatment or recommendations for further rehabilitation in a neurological hospital setting. This makes an initially benign cause a trigger for chronic dizziness complaints, subsequently leading to various functional disorders that slow recovery, reduce productivity, and significantly impair patients' quality of life. On November 22, 2025, an expert council was held to discuss important issues related to the diagnosis, management, and rehabilitation of patients with acute vestibular vertigo. Based on the results, a patient management strategy was proposed.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 3. Vyp. 2","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147629317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Network analysis of psychopathological symptoms in patients with schizophrenia as a model for studying the clinical presentation].","authors":"E G Kornetova, S A Galkin, A N Kornetov, D A Petkun, S A Ivanova","doi":"10.17116/jnevro202612607163","DOIUrl":"https://doi.org/10.17116/jnevro202612607163","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the validity of the six-factor model of the Positive and Negative Syndrome Scale (PANSS) using network analysis and to examine the relationships between depression, anxiety, and symptoms associated with schizophrenia.</p><p><strong>Material and methods: </strong>The study included a cohort of 150 inpatients diagnosed with schizophrenia. The severity of psychopathological symptoms was assessed using the PANSS based on a six-factor model. The study also utilized the Hamilton Depression Rating Scale (HDRS) and the Hamilton Anxiety Rating Scale (HARS). Network analysis was performed using the R statnet package.</p><p><strong>Results: </strong>The findings revealed that the highest centrality rates were attributed to the disorganized, negative, and excitation factors within the PANSS scale. Anxiety scores derived from HARS were found to be significantly associated with G16 (active social avoidance), G6 (depression), N2 (emotional withdrawal), and G3 (guilt feelings), which correspond to elements within the negative, depressive, and disorganized factors. In addition, HDRS depression scores demonstrated associations with G6 and N2, representing the depressive and negative factors. A correlation was also observed between the scores from both assessment scales.</p><p><strong>Conclusions: </strong>The network analysis indicated that depressive symptoms evaluated through the HDRS, alongside anxiety symptoms assessed via HARS, hold substantial significance among the psychopathological presentations observed in patients with schizophrenia. These symptoms exhibit a close interrelationship with components of the negative, depressive, and disorganized factors as identified within the PANSS model. In addition, the analysis substantiated the validity of the PANSS six-factor model.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 7","pages":"63-68"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148686959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Botulinum therapy within a three-stage medical rehabilitation framework for patients with disorders of craniofacial muscles].","authors":"S E Khatkova, Yu S Kraynova, O A Teryaeva, O A Pogoreltseva, O S Pavlyuchenkova, A V Golovanova","doi":"10.17116/jnevro202612608288","DOIUrl":"https://doi.org/10.17116/jnevro202612608288","url":null,"abstract":"<p><p>Disorders of craniofacial muscles (CFM) frequently arise from various conditions and injuries affecting the central and peripheral nervous systems, as well as from neurosurgical, reconstructive, and cosmetic interventions. The principal clinical manifestations include facial asymmetry, lagophthalmos, paralytic strabismus, synkinesis, contractures, trismus, bruxism, temporomandibular joint dysfunction, chronic facial pain, and sialorrhea. Such disorders not only restrict daily functioning but also lead to significant psychosocial maladjustment, a decline in quality of life, and increased disability among affected individuals. Despite the high prevalence of CFM dysfunction, contemporary methods for the medical rehabilitation of patients remain inconsistent, with poor regulation governing continuity among the various stages of care. This paper posits the establishment of «facial rehabilitation» as a distinct interdisciplinary approach within medical rehabilitation, integrated into the established three-stage medical rehabilitation framework in the Russian Federation. A thorough review of current literature and pertinent Russian regulatory documents has been conducted. The objectives of facial rehabilitation across the first, second, and third stages are analyzed, along with the role of botulinum therapy in comprehensive rehabilitation programs aimed at restoring impaired functions. The potential of this method for a wide range of functional, structural, and autonomic disorders of the face is considered, given the multifaceted mechanisms of action of botulinum toxin type A (BTA), including muscle-relaxant, antinociceptive, neuromodulatory, and anti-inflammatory effects. The authors present their own clinical experience demonstrating the effective use of botulinum therapy to treat trismus, paralytic strabismus, lagophthalmos, and pronounced facial asymmetry in patients with complications from neurological conditions and injuries. The findings underscore the efficacy of integrating botulinum therapy into three-stage medical rehabilitation programs, highlighting its role in preventing complications and enhancing rehabilitation potential and quality of life for patients.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 8. Vyp. 2","pages":"88-99"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Success rates of revascularization methods in ischemic stroke in clinical practice].","authors":"S V Kotov, M V Sutormin, E S Dzhvaridze, E V Isakova","doi":"10.17116/jnevro202612608245","DOIUrl":"10.17116/jnevro202612608245","url":null,"abstract":"<p><strong>Objective: </strong>To compare the success rates of various revascularization methods in patients presenting with ischemic stroke (IS) in a real-world practice.</p><p><strong>Material and methods: </strong>An open-label prospective observational study was conducted involving 225 patients diagnosed with IS. The patients were categorized into three distinct groups: Group 1 (67.1% of participants) received systemic thrombolytic therapy [TLT], Group 2 (15.6% of participants) received intravascular thrombectomy (IVTE), and Group 3 (17.3% of participants) received combined TLT+IVTE, referred to as bridge therapy. The assessment of neurological status was conducted using the National Institutes of Health Stroke Scale (NIHSS), functional activity was evaluated according to the modified Rankin Scale (mRs), mobility was measured based on the Rivermead Mobility Index (RMI), and the completeness of perfusion recovery was determined using the Thrombolysis in Cerebral Infarction (TICI) classification for Groups 2 and 3. Functional recovery was evaluated after 6 months using the Barthel Index (BI).</p><p><strong>Results: </strong>Demographic characteristics across the groups were comparable. Statistically significant differences in the timing of revascularization were observed: Groups 1 and 3 received treatment within approximately 2.5 hours, whereas Group 2 received treatment within 6 hours. Baseline stroke severity, as measured by the NIHSS, was significantly higher in Groups 2 and 3 (<i>p</i><0.002). The TICI scores of 2b-3 were noted in 74.3% of patients in Group 2 and 79.5% in Group 3, reflecting the substantial technical success rates of endovascular interventions. At discharge, patients in Group 1 exhibited the greatest reduction in neurological deficit (<i>p=</i>0.011). Independence in daily activities (rated 0-2 on the mRs) was achieved by 28.5% of patients in Group 1, 8.6% in Group 2, and 12.8% in Group 3. The mortality rate over 6 months was 24.5% in Group 1, 51.4% in Group 2, and 33.3% in Group 3 (<i>p=</i>0.002 between Groups 1 and 2). The BI at the six-month mark was significantly higher in Group 1 (90 [60; 100]) compared to Groups 2 (60 [50; 85]) and 3 (65 [50; 97.5]).</p><p><strong>Conclusions: </strong>The findings suggest that systemic TLT, particularly in patients with less severe strokes and timely treatment initiation, is associated with the most favorable outcomes. In contrast, IVTE and combination therapy (bridge therapy) administered to patients with NIHSS scores exceeding 10 and/or large vessel occlusions demonstrate comparable technical success rates but yield less favorable clinical outcomes. Critical determinants influencing outcomes include the duration from symptom onset to intervention and baseline stroke severity.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 8. Vyp. 2","pages":"45-53"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148892651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Multicenter ambispective observational study of oral anticoagulants in cerebral venous thrombosis (Eurasian Registry of Cerebral Venous Thrombosis - ER-CVT)].","authors":"A M Alasheev, A D Smolkin, A A Kulesh, N N Strambovskaya, E A Grigoriev, D M Plotnikov, S A Chugunova, S E Chuprina, N V Komissarova, L V Timchenko, A A Bort, S V Tabakman, N A Shamalov","doi":"10.17116/jnevro202612608254","DOIUrl":"10.17116/jnevro202612608254","url":null,"abstract":"<p><strong>Objective: </strong>To compare the safety profile of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in the management of cerebral venous thrombosis (CVT) following initial parenteral therapy.</p><p><strong>Material and methods: </strong>The Eurasian Registry of Cerebral Venous Thrombosis (ER-CVT) is a multicenter, ambispective, comparative cohort study conducted in accordance with the DOAC-CVT protocol. The primary endpoint was the composite of symptomatic venous thromboembolism (VTE) and/or major bleeding, as defined by ISTH criteria, during a 6-month follow-up period. Secondary endpoints included complete recanalization, functional outcomes as assessed by the modified Rankin scale (mRs), and the frequency of changes in anticoagulant therapy over a 12-month follow-up. The dataset was compiled from 12 cities across Russia. Of the total cases, 88 (77%) were recorded retrospectively. Between May 2023 and March 2025, 112 patients diagnosed with CVT from 13 sites In Russia were enrolled in the study. The median age of participants was 41 years (range: 33 to 55 years), with 73 (64%) being female. Brain MRI confirmed the diagnosis of CVT in 81 (72%) cases. Hemorrhagic lesions, as evident in neuroimaging, were observed in 44 (39%) cases. The final analysis of therapeutic efficacy was conducted with 104 patients (92.9% of the initial sample of 112), comprising 72 patients receiving warfarin therapy and 32 receiving DOACs.</p><p><strong>Results: </strong>Following the completion of initial parenteral anticoagulant therapy, 72 patients commenced VKA therapy, and 32 initiated treatment with DOACs. Eight patients who commenced an unspecified oral anticoagulant were excluded from the efficacy analysis. No events of recurrent symptomatic VTE, major bleeding, mortality, clinically significant non-major bleeding, or arterial thromboembolism were reported. In the VKA cohort, 6.9% of patients transitioned to DOACs, whereas no patients in the DOAC group switched to other anticoagulants. Ordinal regression analysis demonstrated significantly increased odds of complete recanalization at 6 and 12 months (OR=60.4; 95% CI 3.1-1191.6, <i>p</i>=0.007, and OR=52.0; 95% CI 2.83-956.3, <i>p</i>=0.008, respectively), as well as improved functional outcomes (as measured by the mRs scale) at 12 months (OR=4.2; 95% CI 1.4-2.5, <i>p</i>=0.012) within the DOAC cohort.</p><p><strong>Conclusions: </strong>The findings from the ER-CVT study indicate a comparably safe profile for both DOACs and VKAs in treating CVT post-initial parenteral therapy. DOACs demonstrated superior recanalization rates and enhanced functional outcomes.</p>","PeriodicalId":56370,"journal":{"name":"Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova","volume":"126 8. Vyp. 2","pages":"54-59"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148893111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}